skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Nephroprotective action of glycosaminoglycans: why the pharmacological properties of sulodexide might be reconsidered

Review

(2505) Views  (1054) Full article downloads

Authors: Antonio V Gaddi, Arrigo FG Cicero, Giovanni Gambaro

Published Date July 2010 Volume 2010:3 Pages 99 - 105
DOI: http://dx.doi.org/10.2147/IJNRD.S5943

Antonio V Gaddi1, Arrigo FG Cicero1, Giovanni Gambaro2

1Atherosclerosis and Metabolic disease Research Unit, Internal Medicine, Aging and Kidney diseases Dept., University of Bologna, Italy; 2Nephrology and Dialysis Unit, Gemelli University Hospital, Sacred Heart Catholic University, Rome, Italy

Abstract: A relatively large body of evidence supports the notion that glomerular capillary wall and mesangial alterations in diabetic nephropathy involve biochemical alterations of glycoproteins in these structures. Evidence in experimental animals rendered diabetic reveals that the administration of heparin and other anionic glycoproteins can effectively prevent the biochemical alterations that promote albuminuria. Moreover, angiotensin II inhibits heparan sulfate synthesis, while heparins modulate angiotensin II signaling in glomerular cells, inhibiting aldosterone synthesis and lowering proteinuria in diabetes patients. Sulodexide, a mixture of heparin and dermatan sulfate, appears to be a promising treatment for diabetic proteinuria partially resistant to renin–angiotensin system blocking agents. Sulodexide prevents heparan sulfate degradation, thus allowing reconstruction of heparan sulfate content and restoration of glomerular basement membrane ionic permselectivity. The antiproteinuric effect appears to be mainly related to the basal proteinuria and consequently to the duration of treatment in a relatively large number of small clinical trials. On the other hand, several sulodexide pharmacodynamic properties could improve the prognosis of chronic kidney disease patients, also independently from its antiproteinuric effect. However, sulodexide development as an antiproteinuric drug needs to be continued, in order to define which kind of patients could better respond to this treatment.

Keywords: glycosaminoglycans, sulodexide, albuminuria, proteinuria, diabetic nephropathy






 

Other articles by Dr Arrigo Cicero



Readers of this article also read:

Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
The use of everolimus in renal-transplant patients
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Potential renovascular hypertension, space missions, and the role of magnesium
Critical appraisal of the role of glucosamine and chondroitin in the management of osteoarthritis of the knee
Ego mechanisms of defense are associated with patients’ preference of treatment modality independent of psychological distress in end-stage renal disease
Can a gentamicin-specific chart reduce neonatal medication errors?
Health literacy and health seeking behavior among older men in a middle-income nation
Dashboards in neonatology
Everolimus-eluting stents: update on current clinical studies
  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio